Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: a True Effect or a Bias? A Systematic Review & Meta-Analysis

被引:24
|
作者
Leshem, Regina [1 ]
Bar-Oz, Benjamin [2 ]
Diav-Citrin, Orna [1 ,3 ]
Gbaly, Siham [1 ]
Soliman, Jessica [1 ]
Renoux, Christel [4 ]
Matok, Ilan [1 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Ein Kerem Campus, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel
[3] Minist Hlth, Israeli Teratol Informat Serv, Jerusalem, Israel
[4] McGill Univ, Montreal, PQ, Canada
关键词
SSRI's; SNRI's; antidepressants; ASD; ADHD; prenatal exposure; pregnancy; MATERNAL ANTIDEPRESSANT USE; PLACENTAL-TRANSFER; PRETERM BIRTH; FUNNEL-PLOT; DEPRESSION; EXPOSURE; OUTCOMES;
D O I
10.2174/1570159X19666210303121059
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background and objective: An inconsistent association between exposure to SSRIs and SNRIs and the risk for ASD and ADHD in the Offspring was observed in observational studies. Some suggest that the reported association might be due to unmeasured confounding. We aimed to study this association and to look for sources of bias by performing a systematic review and meta-analysis. Methods: Medline, Embase, and the Cochrane Library were searched up to June 2019 for studies reporting on ASD and ADHD in the Offspring following exposure during pregnancy. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random-effects models and odds ratios (OR), and 95% confidence intervals (CI) were calculated for each outcome using the adjusted point estimate of each study. Results: Eighteen studies were included in the meta-analysis. We found an association between SSRIs/SNRIs prenatal use and the risk for ASD and ADHD (OR=1.42, 95% CI: 1.23-1.65, I-2=58%; OR=1.26, 95% CI: 1.07-1.49, I-2=48%, respectively). Similar findings were obtained in women who were exposed to SSRIs/SNRIs before pregnancy, representing statistically significant association with ASD (OR=1.39, 95% CI: 1.24-1.56, I-2=33%) and ADHD (OR=1.63, 95% CI: 1.50-1.78, I-2=0%) in the Offspring, although they were not exposed to those medications in utero. Conclusions: Although we found an association between exposure to SSRIs/SNRIs during pregnancy and the risk for ASD and ADHD, an association with those disorders was also present for exposure pre-pregnancy, suggesting that the association might be due to unmeasured confounding. We are aiming to further assess the role of potential unmeasured confounding in the estimation of the association and perform a network meta-analysis.
引用
收藏
页码:896 / 906
页数:11
相关论文
共 50 条
  • [21] Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: Need for further analysis
    Kobayashi, Tohru
    Matsuyama, Tasuku
    Takeuchi, Masanobu
    Ito, Shinya
    REPRODUCTIVE TOXICOLOGY, 2017, 67 : 148 - 148
  • [22] Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder
    Hu, Xiaojing
    Pan, Lili
    Li, Wenjie
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 32 (05): : 511 - 522
  • [23] Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials
    Huang, Kai-Lin
    Lui, Wan-Chen
    Wang, Ying-Yue
    Hu, Gwo-Chi
    Lui, Chien-Hung
    Lee, Wei-Ying
    Hsu, Chien-Chi
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 (07): : 663 - 671
  • [24] SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR STROKE RECOVERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Mead, G.
    Legg, L.
    Hua, X.
    Wu, S.
    Hackett, M.
    Hsieh, C. -F.
    Barugh, A.
    Lundstrom, E.
    Lindgren, L.
    Rudberg, A. S.
    Kutlubaev, M.
    Tilney, R.
    Dennis, M.
    Hankey, G.
    INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (3_SUPPL) : 15 - 15
  • [25] Selective Serotonin Reuptake Inhibitors for Stroke Recovery A Systematic Review and Meta-analysis
    Mead, Gillian E.
    Hsieh, Cheng-Fang
    Lee, Rebecca
    Kutlubaev, Mansur
    Claxton, Anne
    Hankey, Graeme J.
    Hackett, Maree
    STROKE, 2013, 44 (03) : 844 - +
  • [26] Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis
    Khanassov, Vladimir
    Hu, Jingyi
    Reeves, David
    van Marwijk, Harm
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (12) : 1688 - 1708
  • [27] A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    Papakostas, George I.
    Nelson, J. Craig
    Kasper, Siegfried
    Moeller, Hans-Juergen
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 122 - 127
  • [28] Risk of Intracranial Hemorrhage and Utilization of Selective Serotonin Reuptake inhibitors: A Systematic Review and Meta-analysis
    Alsayat, Jouf Yousef
    Abu Zahirah, Mohammad Owaidh
    Almutairi, Maha Fahad
    Ammar, Ahmed Abdulrahman
    Almahboob, Ghaida Saleh
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2021, 11 (01) : 1228 - 1231
  • [29] The impact of selective serotonin reuptake inhibitors on the risk of intracranial haemorrhage: A systematic review and meta-analysis
    Jensen, Melanie P.
    Ziff, Oliver J.
    Banerjee, Gargi
    Ambler, Gareth
    Werring, David J.
    EUROPEAN STROKE JOURNAL, 2019, 4 (02) : 144 - 152
  • [30] Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents A Systematic Review and Meta-analysis
    Locher, Cosima
    Koechlin, Helen
    Zion, Sean R.
    Werner, Christoph
    Pine, Daniel S.
    Kirsch, Irving
    Kessler, Ronald C.
    Kossowsky, Joe
    JAMA PSYCHIATRY, 2017, 74 (10) : 1011 - 1020